Zimmer Biomet Holdings (NYSE: ZBH) reported Q1 EPS of $1.70, $0.35 better than the analyst estimate of $1.35. Revenue for the quarter came in at $1.78 billion versus the consensus estimate of $1.79 billion.

• First quarter net sales of $1.784 billion decreased 9.7%, and decreased 8.9% on a constant currency basis
• First quarter diluted loss per share was $2.46; adjusted diluted earnings per share were $1.70

"While our full first quarter results have been impacted by the global spread of COVID-19 and the deferral of elective procedures, our operational performance prior to the COVID-19 disruption was trending ahead of our expectations," said Bryan Hanson, President and CEO of Zimmer Biomet. "Over the past two years, we have made significant strides in reshaping and evolving Zimmer Biomet. This progress has better positioned us to address the COVID-19 challenge. We have an innovative and mobilized team, operational scale and increased financial flexibility – all of which we are using to support healthcare professionals and patients. I continue to be so proud of our global team and our collective, unyielding commitment to the ZB mission to better the lives of people around the world."

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.